Takeda Pharmaceutical Co ADR vs Teva- Pharmaceutical Industries Ltd

Takeda Pharmaceutical Co ADR (TAK) is overvalued and Teva- Pharmaceutical Industries Ltd (TEVA) is overvalued.

Both trade above our estimate of their intrinsic value. TEVA is the closer of the two: -110%, against -521% for TAK.

Values as of the 17 Nov 2026 close.

Takeda Pharmaceutical Co ADR (TAK)

Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $3.49; the price of $21.64 is 521% above that value, and 75% of that value comes from beyond year five.

Leak Score: free with an account

Teva- Pharmaceutical Industries Ltd (TEVA)

Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $20.28; the price of $42.62 is 110% above that value, and 73% of that value comes from beyond year five.

Leak Score: free with an account

MetricTAKTEVA
VerdictOvervaluedOvervalued
Price$21.64$42.62
Intrinsic value$3.49$20.28
Margin of safety-521%-110%
Market cap$69.1B$49.7B
Revenue growth, 5 years-0.2%0.8%
Operating margin17.9%19.2%
Net margin0.8%2.9%
Return on equity0.5%6.7%
Debt to equity0.622.13
P/E351.9x100.3x
Forward P/E32.6x13.7x
P/B1.5x6.2x
Dividend yield3.0%—

All stocks in Drug Manufacturers - Specialty & Generic